Marengo Therapeutics taps Dr. Kevin Chin as chief medical officer

Cancer immunotherapy development company Marengo Therapeutics appointed Kevin Chin, MD, its chief medical officer. 

Advertisement

Dr. Chin, an oncology specialist, most recently served as senior vice president and head of clinical development at 2Seventy Bio, a biotechnology company, according to a March 1 news release from Marengo. 

In his new role, Dr. Chin will manage the development of the company’s clinical portfolio, the release said. 

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

From fragmentation to operational flow: Solving the healthcare workforce puzzle

Tuesday, August 11
1:00 PM - 2:00 PM CDT

Presenters: Dr. Pat Hunt, QGendaAndrea Daugherty, MHA, CISSP, CHCIO, CDH-E, Arrowhead Regional Medical CenterElizabeth Lindsay-Wood, MBA, CHCIO, CDH-E, Moffitt Cancer CenterDeb Muro, El Camino HealthJohn Tejeda, D.H.A., MLS, MPAS, DFAAPA, LSSBB, FACHE, Vascular and Neuroscience Institute

Advertisement

Next Up in Leadership

Advertisement

Comments are closed.